Epidermolysis Bullosa Market
May 27, 2025
Gilead’s TRODELVY Shows PFS Benefit in 1L Metastatic TNBC; Otsuka’s Sibeprenlimab Gets FDA Priority Review for IgA Nephropathy; Liquidia Wins FDA Nod for YUTREPIA in PAH and PH-ILD; GSK’s BLENREP Combos Get CHMP Backing in Myeloma; Relief Therapeutics Receives FDA Rare Pediatric Disease Tag for RLF-TD011
Gilead’s TRODELVY Demonstrates Significant PFS Benefit in First-Line Metastatic TNBC in ASCENT-03 Trial Gilead Sciences has announced positive topline results from the Phase III ASCENT-03 trial of TRODELVY (sacituzumab govitecan-hziy) in first-line metastatic triple-negative breast cancer (mTNBC) patients who ar...
Read More...
Mar 25, 2024
Gene Therapies for Epidermolysis Bullosa Treatment: The Next Frontier in Dermatology
Epidermolysis bullosa is a genetic skin condition marked by severe skin sensitivity and the formation of blisters even from minor friction or injury. This disorder arises from genetic changes that impact the proteins crucial for upholding the skin’s structural strength. The degree of severity in epidermolysis bullo...
Read More...
Nov 02, 2020
Pharma Players Line Up To Launch Novel Therapies Fueling Epidermolysis Bullosa Market Size
Epidermolysis bullosa (EB) places a significant socioeconomic burden on patients. Several reports stated that Epidermolysis bullosa had a considerable negative impact on the quality of the lives of patients. Although it is a rare disease, EB is a cause of significant morbidity and mortality among the affected indiv...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
